Faster global financial news!
Revolution Medicines
-
BeiGene's net profit for the first half of the year surged by 385.8% year-on-year to US$464 million, with total revenue reaching US$3.219 billion.
BeiGene announced its results for the six months ended June 30, 2026, with total revenue increasing by 32.3% year-on-year. The global sales of its flagship product, BRUKINSA® (zanubrutinib), reached U
-
Billionaire investor Stanley Druckenmiller's family office increased its stake in Revolution Medicines (RVMD) by 26.5% in the second quarter of 2026.
Druckenmiller's Duquesne Family Office previously initiated a position in Revolution Medicines in the first quarter of 2026. Although Wall Street analysts only expect the biotech company's stock price
-
The family office run by billionaire Stanley Druckenmiller purchased 316,000 shares of Revolution Medicines (RVMD) in the first quarter; the company’s stock price has risen more than 134% so far this year.
Duquesne Family Office, run by billionaire investor Stanley Druckenmiller, purchased 316,000 shares of biotechnology company Revolution Medicines (RVMD) in the first quarter.The company’s stock price
-
BeiGene's net profit for the first half of the year surged by 385.8% year-on-year to US$464 million, with total revenue reaching US$3.219 billion.
BeiGene announced its results for the six months ended June 30, 2026, with total revenue increasing by 32.3% year-on-year. The global sales of its flagship product, BRUKINSA® (zanubrutinib), reached U
-
Billionaire investor Stanley Druckenmiller's family office increased its stake in Revolution Medicines (RVMD) by 26.5% in the second quarter of 2026.
Druckenmiller's Duquesne Family Office previously initiated a position in Revolution Medicines in the first quarter of 2026. Although Wall Street analysts only expect the biotech company's stock price
-
The family office run by billionaire Stanley Druckenmiller purchased 316,000 shares of Revolution Medicines (RVMD) in the first quarter; the company’s stock price has risen more than 134% so far this year.
Duquesne Family Office, run by billionaire investor Stanley Druckenmiller, purchased 316,000 shares of biotechnology company Revolution Medicines (RVMD) in the first quarter.The company’s stock price
- No data
Revolution Medicines
24H Trending
-
1
SK hynix in talks with Intel over potential US memory production agreement
-
2
Fetch.ai (FET) Token Analysis: Project Status and Investment Considerations
-
3
Bybit to adjust risk limits and leverage for selected perpetual contracts including 1000XECUSDT and BLASTUSDT, effective Sep 18, 2026
-
4
Anthropic, after calling for an AI slowdown, has signed its first data center lease in Australia, planning a total capacity of 2.16 GW.
-
5
Nikkei: Japan's MUFG Bank to Introduce Guidelines for Financing Defense Industry
-
6
Zhipu AI's CoWork business in China is progressing rapidly, with industry orders exceeding 1 billion yuan within one month of GLM-5.3's release.
-
7
Markets are cautiously optimistic ahead of the Federal Reserve's decision, with U.S. Treasuries slightly stronger, crude oil gains narrowing, and equity index futures holding steady.
-
8
Turkish Stocks Fall More Than 5% Amid Deepening Fund Redemption Woes
-
9
UK FCA Issues New Guidance for Crypto Assets, Preparing Firms for Authorization Applications Opening September 2026
-
10
FLWR Coin Status Analysis: Market Performance and Prospects of Two Tokens with the Same Name
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
